MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA
Clinical trials for MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to cut blood transfusions for bone marrow disease patients
Disease control Recruiting nowThis study tests an experimental drug called DISC-0974 in about 150 adults with myelofibrosis or myelodysplastic syndrome (MDS) who also have anemia. The goal is to see if the drug can reduce the need for blood transfusions and increase red blood cell levels. The study is in earl…
Matched conditions: MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA
Phase: PHASE1, PHASE2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo hopes to improve myelofibrosis treatment
Disease control Recruiting nowThis early-phase trial is testing whether adding abemaciclib to the standard drug ruxolitinib is safe and effective for people with myelofibrosis, a type of bone marrow cancer. The study will enroll 18 adults who have been on ruxolitinib for at least 12 weeks. Researchers will mo…
Matched conditions: MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Massive new study aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis long-term observational study is enrolling 5,000 adults with myeloproliferative neoplasms (MPNs)—rare blood cancers like polycythemia vera and myelofibrosis. Researchers will collect health records, patient surveys, and insurance data over at least five years to track sympto…
Matched conditions: MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC